

# TECHNICAL CONSIDERATIONS AND CASE DEFINITIONS TO IMPROVE SURVEILLANCE FOR VIRAL HEPATITIS

TECHNICAL REPORT



# **TECHNICAL CONSIDERATIONS AND CASE DEFINITIONS TO IMPROVE SURVEILLANCE FOR VIRAL HEPATITIS**

WHO Library Cataloguing-in-Publication Data

Technical considerations and case definitions to improve surveillance for viral hepatitis: technical report.

1.Hepatitis, Viral, Human - epidemiology. 2.Public Health Surveillance. I.World Health Organization.

ISBN 978 92 4 154954 7

(NLM classification: WC 536)

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website ([http://www.who.int/about/licensing/copyright\\_form/index.html](http://www.who.int/about/licensing/copyright_form/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design and layout: [blossoming.it](http://blossoming.it)

# TABLE OF CONTENTS

<b>Acknowledgements</b>	<b>7</b>
<b>Funding and declarations of interest</b>	<b>7</b>
<b>Abbreviations and acronyms</b>	<b>8</b>
<b>Terminology</b>	<b>9</b>
<b>Executive summary</b>	<b>10</b>
<b>1. Background</b>	<b>15</b>
1.1. Viral hepatitis is a global public health problem	15
1.2. Viral hepatitis is preventable	15
1.3. Viral hepatitis is a silent epidemic	15
1.4. Surveillance can effectively direct prevention, control and treatment	16
1.5. Need for stronger viral hepatitis surveillance	16
<b>2. Aim of these technical considerations</b>	<b>17</b>
2.1. Audience	17
2.2. Scope	17
2.3. Purpose	17
2.4. Use of this document	17
<b>3. How this document was prepared</b>	<b>18</b>
<b>4. Epidemiology of viral hepatitis</b>	<b>19</b>
4.1. Specific aspects of viral hepatitis epidemiology	19
4.2. The five hepatitis viruses	22
<b>5. Purpose and methods of viral hepatitis surveillance</b>	<b>24</b>
5.1. Detect outbreaks, monitor trends in incidence and identify risk factors for new, incident infections	24
5.2. Estimate the burden of chronic infection	28
5.3. Estimate the burden of sequelae	33
<b>6. Virus-specific surveillance</b>	<b>35</b>
6.1. Hepatitis A	35
6.2. Hepatitis B	37
6.3. Hepatitis C	39
6.4. Hepatitis E	42

<b>7. Use of surveillance information to evaluate programmes</b>	<b>44</b>
7.1. Prevention of new infections	44
7.2. Use of estimates of the burden of chronic prevalent infections	44
7.3. Use of estimates of the burden of sequelae	46
<b>8. Organizing viral hepatitis surveillance</b>	<b>47</b>
8.1. Engaging stakeholders, including key populations	48
8.2. Assessing the situation	49
8.3. Integrating with other data sources, programmes and systems	49
<b>9. Considerations for in vitro diagnosis</b>	<b>50</b>
9.1. Testing strategy	50
9.2. Quality assurance	50
9.3. Testing considerations for case reporting	51
9.4. Testing considerations for biomarker surveys	52
9.5. Rapid diagnostic tests	52
9.6. Dried blood spot specimens	52
9.7. Testing stored specimens	53
9.8. Molecular studies	53
<b>10. Ethical considerations</b>	<b>54</b>
10.1. Key ethical principles for surveillance	54
10.2. Security and confidentiality	55
10.3. Informed consent	55
10.4. Returning test results to individuals	55
10.5. Linked and unlinked anonymous data	56
<b>11. Managing, analysing and communicating viral hepatitis surveillance data</b>	<b>57</b>
11.1. Managing data to ensure quality	57
11.2. Analysing data	57
11.3. Communicating results	58
11.4. Engaging stakeholders with surveillance information	58
<b>12. Evaluation of viral hepatitis surveillance</b>	<b>59</b>
12.1. Attributes of surveillance systems	59
12.2. Key attributes of viral hepatitis surveillance	59
<b>References</b>	<b>61</b>
<b>Annex 1: Template case report form for acute or chronic viral hepatitis</b>	<b>67</b>
<b>Annex 2: Tables</b>	<b>68</b>

# ACKNOWLEDGEMENTS

The chair of the Technical Consultation to Develop Guidelines for the Surveillance of Viral Hepatitis in Low- and Middle-income Countries was Arnaud Fontanet (Institut Pasteur and National Agency for AIDS Research [ANRS]).

## **The following experts participated in the technical consultation meeting:**

Patricia Angeleri (Ministry of Health, Argentina), Rana Jawad Asghar (Field Epidemiology & Laboratory Training Programme, Pakistan), Silvano Barbosa de Oliveira (Ministry of Health, Brazil), Iacopo Baussano (International Agency for Research on Cancer, France), Fuqiang Cui (Chinese Center For Disease Control And Prevention, China), Erika Duffell (European Centre for Disease Prevention and Control, Sweden), Mohammad Mehdi Gouya (Ministry of Health & Medical Education, Iran), Janet Hatcher-Roberts (Canadian Society for International Health, Canada), Wolfgang Hladik (Centers for Disease Control and Prevention, USA), Sharon Hutchinson (Health Protection Scotland, UK), Ruth Jiles (Centers for Disease Control and Prevention, USA), Mark Kane (Consultant on Immunization Policy, USA), Ahmed Khatib (Ministry of Health, Tanzania), Mira Kojouharova (National Centre of Infectious and Parasitic Diseases, Bulgaria), Daniel Lavanchy (Consultant, Switzerland), Tinne Lernout (University of Antwerp, Belgium), Alison Marshall (Canadian Society for International Health, Canada), Nenette Motus (International Organization for Migration, Switzerland), Jane Njihia (Public Health Agency of Canada, Canada), Richard Njouom (Centre Pasteur of Cameroon, Cameroon), Gerson Fernando Pereira (Ministry of Health, Brazil), Aminata Sall Diallo (National Senegalese Programme against Hepatitis, Senegal), Maha Talaat (Global Disease Detection and Response Center, Egypt), Eyasu Teshale (Centers for Disease Control and Prevention, USA), Hla Hla (Rosie) Thein (University of Toronto, Canada), Anonh Xeuatvongsa (Ministry of Health, Lao People's Democratic Republic).

## **WHO Staff**

Isabel Bergeri, Jesus Maria Garcia Calleja, Hande Harmanci, Yvan Hutin, Selma Khamassi, Tim Nguyen, Nicole Seguy, Anita Sands, Alexander Spina, Amitabh Suthar and Stefan Wiktor

Miriam Sabin, WHO consultant, coordinated the preparation of these technical considerations, which was then revised by Eyasu Teshale, Stefan Wiktor and Yvan Hutin.

# FUNDING

The development of these technical considerations received support from the US Centers for Disease Control and Prevention, Division of Viral Hepatitis and Public Health Canada.

# ABBREVIATIONS AND ACRONYMS

<b>AIS</b>	AIDS Indicator Survey
<b>ALT</b>	alanine aminotransferase
<b>ANC</b>	antenatal care
<b>anti-HAV</b>	antibody against hepatitis A virus
<b>anti-HBc</b>	antibody against hepatitis B core antigen
<b>anti-HDV</b>	antibody against hepatitis D virus
<b>anti-HEV</b>	antibody against hepatitis E virus
<b>ARV</b>	antiretroviral
<b>CI</b>	confidence interval
<b>DBS</b>	dried blood spot
<b>DHS</b>	Demographic and Health Survey
<b>EIA</b>	enzyme immunoassay
<b>EPI</b>	Expanded Programme of Immunization
<b>EQAS</b>	external quality assessment scheme
<b>HAV</b>	hepatitis A virus
<b>HBeAg</b>	hepatitis B E antigen
<b>HBIG</b>	hepatitis B immune globulin
<b>HBsAg</b>	hepatitis B surface antigen
<b>HBV</b>	hepatitis B virus
<b>HCC</b>	hepatocellular carcinoma
<b>HCV</b>	hepatitis C virus
<b>HDV</b>	hepatitis D virus
<b>HEV</b>	hepatitis E virus
<b>IARC</b>	International Agency for Research on Cancer
<b>IBBS</b>	integrated HIV biobehavioural surveillance
<b>ICD</b>	International Statistical Classification of Diseases and Related Health Problems
<b>IDSR</b>	Integrated Disease Surveillance and Response
<b>IgM</b>	immunoglobulin M
<b>IHR</b>	International Health Regulations

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27100](https://www.yunbaogao.cn/report/index/report?reportId=5_27100)

